(Reuters) -Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have ...

Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui Pharmaceuticals’ investigational cardiovascular disease (CVD) drug in a ...

Under terms of the deal, Merck will gain global rights ... The drug is currently in a Phase II clinical trial in China. 1 “Elevated blood concentrations of Lp(a) provides a well-documented risk factor ...

that was reportedly also involved in negotiations to buy out the company. If approved, it would become a companion to Merck's Bayer-partnered heart failure drug Verquvo (vericiguat), cleared by ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346 ...

Under the latest deal, announced on Tuesday, Merck will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346, worldwide ...